Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI vs Vonoprazan Triple Therapy With or Without Zinc for H. Pylori Eradication
NCT07275827Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vonoprazan and zinc in Helicobacter pylori infection (4 arms), sponsored by Tanta University. Primary endpoint: Helicobacter pylori eradication rate at 8 weeks. Started Feb 2026; status: recruiting.
02
Drugs
vonoprazanzinc
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07275827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275827.